PDF(Pubmed)
Abstract：
UNASSIGNED: Accumulating evidence suggests that metabolic disorders, including type 2 diabetes mellitus (T2DM), can be treated with traditional Chinese medicine formulas, such as the Gegen Qinlian decoction (GQD). This study elucidates the mechanisms by which gut microbes mediate the anti-diabetic effects of GQD.
UNASSIGNED: We conducted a double-blind randomized clinical trial involving 120 untreated participants with T2DM. During the 12-week intervention, anthropometric measurements and diabetic traits were recorded every 4 weeks. Fecal microbiota and serum metabolites were measured before and after the intervention using 16S rDNA sequencing, liquid chromatography-mass spectrometry, and Bio-Plex panels.
UNASSIGNED: Anti-diabetic effects were observed in the GQD group in the human trial. Specifically, glycated hemoglobin, fasting plasma glucose, and two-hour postprandial blood glucose levels were significantly lower in the GQD group than in the placebo group. Additionally, Faecalibacterium was significantly enriched in the GQD group, and the short-chain fatty acid levels were higher and the serum inflammation-associated marker levels were lower in the GQD group compared to the placebo group. Moreover, Faecalibacterium abundance negatively correlated with the levels of serum hemoglobin, fasting plasma glucose, and pro-inflammatory cytokines. Finally, the diabetes-alleviating effect of Faecalibacterium was confirmed by oral administration of Faecalibacterium prausnitzii (DSMZ 17677) in T2DM mouse model.
UNASSIGNED: GQD improved type 2 diabetes primarily by modulating the abundance of Faecalibacterium in the gut microbiota, alleviating metabolic disorders and the inflammatory state.
UNASSIGNED: Registry No. ChiCTR-IOR-15006626.
UNASSIGNED: We conducted a double-blind randomized clinical trial involving 120 untreated participants with T2DM. During the 12-week intervention, anthropometric measurements and diabetic traits were recorded every 4 weeks. Fecal microbiota and serum metabolites were measured before and after the intervention using 16S rDNA sequencing, liquid chromatography-mass spectrometry, and Bio-Plex panels.
UNASSIGNED: Anti-diabetic effects were observed in the GQD group in the human trial. Specifically, glycated hemoglobin, fasting plasma glucose, and two-hour postprandial blood glucose levels were significantly lower in the GQD group than in the placebo group. Additionally, Faecalibacterium was significantly enriched in the GQD group, and the short-chain fatty acid levels were higher and the serum inflammation-associated marker levels were lower in the GQD group compared to the placebo group. Moreover, Faecalibacterium abundance negatively correlated with the levels of serum hemoglobin, fasting plasma glucose, and pro-inflammatory cytokines. Finally, the diabetes-alleviating effect of Faecalibacterium was confirmed by oral administration of Faecalibacterium prausnitzii (DSMZ 17677) in T2DM mouse model.
UNASSIGNED: GQD improved type 2 diabetes primarily by modulating the abundance of Faecalibacterium in the gut microbiota, alleviating metabolic disorders and the inflammatory state.
UNASSIGNED: Registry No. ChiCTR-IOR-15006626.
摘要：
■越来越多的证据表明，代谢紊乱，包括2型糖尿病（T2DM），可以用中药配方治疗，如葛根芩连汤(GQD)。本研究阐明了肠道微生物介导GQD抗糖尿病作用的机制。
■我们进行了一项双盲随机临床试验，纳入了120名未经治疗的T2DM参与者。在为期12周的干预中，每4周记录人体测量和糖尿病特征。使用16SrDNA测序测量干预前后的粪便菌群和血清代谢产物，液相色谱-质谱,和Bio-Plex面板。
■在人试验的GQD组中观察到抗糖尿病作用。具体来说,糖化血红蛋白,空腹血糖，GQD组的餐后两小时血糖水平显着低于安慰剂组。此外,在GQD组中，粪杆菌显著富集，与安慰剂组相比，GQD组的短链脂肪酸水平较高，血清炎症相关标志物水平较低。此外，粪杆菌丰度与血清血红蛋白水平呈负相关,空腹血糖，和促炎细胞因子。最后,通过在T2DM小鼠模型中口服普氏粪杆菌(DSMZ17677)证实了粪杆菌的糖尿病缓解作用。
■GQD主要通过调节肠道微生物群中粪杆菌的丰度来改善2型糖尿病，缓解代谢紊乱和炎症状态。
■登记号.ChiCTR-IOR-15006626。
■我们进行了一项双盲随机临床试验，纳入了120名未经治疗的T2DM参与者。在为期12周的干预中，每4周记录人体测量和糖尿病特征。使用16SrDNA测序测量干预前后的粪便菌群和血清代谢产物，液相色谱-质谱,和Bio-Plex面板。
■在人试验的GQD组中观察到抗糖尿病作用。具体来说,糖化血红蛋白,空腹血糖，GQD组的餐后两小时血糖水平显着低于安慰剂组。此外,在GQD组中，粪杆菌显著富集，与安慰剂组相比，GQD组的短链脂肪酸水平较高，血清炎症相关标志物水平较低。此外，粪杆菌丰度与血清血红蛋白水平呈负相关,空腹血糖，和促炎细胞因子。最后,通过在T2DM小鼠模型中口服普氏粪杆菌(DSMZ17677)证实了粪杆菌的糖尿病缓解作用。
■GQD主要通过调节肠道微生物群中粪杆菌的丰度来改善2型糖尿病，缓解代谢紊乱和炎症状态。
■登记号.ChiCTR-IOR-15006626。
